Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, oxaliplatin,
capecitabine, and irinotecan hydrochloride, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Giving more than
one drug (combination chemotherapy) and giving the drugs in different combinations may kill
more tumor cells. Monoclonal antibodies, such as bevacizumab and cetuximab, can block tumor
growth in different ways. Some block the ability of tumor cells to grow and spread. Others
find tumor cells and help kill them or carry tumor-killing substances to them. Giving
combination chemotherapy together with bevacizumab or cetuximab may kill more tumor cells.
PURPOSE:To evaluate the use of standard (KRAS) and experimental (thymidine phosphorylase,
ERCC1 and BRAF) tumor testing can aid in selecting chemotherapy regimens